By blocking paracellular phosphate transport, tenapanor added to phosphate binders may improve the hyperphosphatemia management in patients on maintenance dialysis, a study found.
Adding aliskiren to losartan in patients with nondiabetic chronic kidney disease does not result in a greater renal protection and increases their risk of hyperkalemia, a study found.
Patients with CKD who discontinued ACE inhibitors or angiotensin receptor blockers after a hyperkalemia episode had a 2.6-fold increased risk of all-cause mortality compared with patients who continued taking the drugs.
In a phase 3 trial, difelikefalin, a kappa opioid receptor agonist, significant decreased itching and improved itching-related quality of life among dialysis patients suffering from pruritus.
Adult patients who used angiotensin receptor blockers prior to surgery had significant 30% increased odds of acute kidney injury, an Icelandic study found.
In a study, spironolactone treatment was not significantly better than placebo in preventing diabetic nephropathy in patients with high-risk type 2 diabetes.
In a pooled analysis of data from 3 studies, patiromer lowered potassium levels into a target range of 3.8 to 5.0 mEq/L in 92.5% and 96.8% of patients with baseline potassium levels of 6.0 mEq/L or higher and less than 6.0 mEq/L, respectively.